Updates are available Correction dated 2019-11-06
Click to view Correction: https://doi.org/10.1186/s13229-019-0288-y
-
Authors
Frohlich, Joel https://orcid.org/0000-0001-8382-4344
Reiter, Lawrence T.
Saravanapandian, Vidya
DiStefano, Charlotte
Huberty, Scott
Hyde, Carly
Chamberlain, Stormy
Bearden, Carrie E.
Golshani, Peyman
Irimia, Andrei
Olsen, Richard W.
Hipp, Joerg F.
Jeste, Shafali S.
-
Funding
Funding for this research was provided by:
NIH (U54 HD87101)
NIH/NIMH (R01MH101198)
Foundation for Prader-Willi Research (Grant #20160852)
Dup15q Alliance (2014460)
Shainberg Neuroscience Fund
- License Information
-
More Information
Article History
Received: 7 March 2019
Accepted: 11 June 2019
First Online: 3 July 2019
Change Date: 6 November 2019
Change Type: Correction
Change Details: Following publication of the original article [1], we have been notified that the Ethics statement of the articles should be changed. The Ethics statement now reads:
Ethics approval and consent to participate
: All EEG studies and analyses were performed with institutional review board (IRB) and/or National Research Ethics Service approval.
: Not applicable
: Joel Frohlich is a former employee of F. Hoffmann-La Roche Ltd. (October 2016 – July 2017). Stormy Chamberlain has received research funding from Levo Therapeutics. Joerg F. Hipp is an employee of F. Hoffmann-La Roche Ltd. Shafali Jeste: serves as a consultant for and has received funding from F. Hoffmann-La Roche Ltd. and Yamo Pharmaceuticals. All the other authors declare that they have no competing interests.
